$18.78
5.92% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
JE00BYSS4X48
Symbol
NVCR

Novocure Ltd. Stock price

$18.78
+2.04 12.19% 1M
-4.37 18.88% 6M
+3.85 25.79% YTD
+6.87 57.68% 1Y
-80.95 81.17% 3Y
-73.96 79.75% 5Y
+0.50 2.74% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+1.05 5.92%
ISIN
JE00BYSS4X48
Symbol
NVCR
Sector

Key metrics

Market capitalization $2.03b
Enterprise Value $1.74b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 3.02
P/S ratio (TTM) P/S ratio 3.52
P/B ratio (TTM) P/B ratio 5.63
Revenue growth (TTM) Revenue growth 14.63%
Revenue (TTM) Revenue $577.74m
EBIT (operating result TTM) EBIT $-150.19m
Free Cash Flow (TTM) Free Cash Flow $-78.21m
Cash position $963.68m
EPS (TTM) EPS $-1.39
P/E forward negative
P/S forward 3.40
EV/Sales forward 2.92
Short interest 6.58%
Show more

Is Novocure Ltd. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Novocure Ltd. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Novocure Ltd. forecast:

4x Buy
57%
3x Hold
43%

Analyst Opinions

7 Analysts have issued a Novocure Ltd. forecast:

Buy
57%
Hold
43%

Financial data from Novocure Ltd.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
578 578
15% 15%
100%
- Direct Costs 135 135
9% 9%
23%
442 442
17% 17%
77%
- Selling and Administrative Expenses 371 371
1% 1%
64%
- Research and Development Expense 210 210
6% 6%
36%
-139 -139
35% 35%
-24%
- Depreciation and Amortization 11 11
1% 1%
2%
EBIT (Operating Income) EBIT -150 -150
33% 33%
-26%
Net Profit -150 -150
24% 24%
-26%

In millions USD.

Don't miss a Thing! We will send you all news about Novocure Ltd. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Novocure Ltd. Stock News

Neutral
Business Wire
5 days ago
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure data at 2024 SNO annual meeting highlights product innovation and real-world evidence for TTFields therapy in glioblastoma.
Neutral
Business Wire
5 days ago
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--FDA approves Novocure's Innovative HFE transducer arrays for use with Optune Gio® for glioblastoma.
Neutral
Seeking Alpha
27 days ago
NovoCure Limited (NASDAQ:NVCR ) Q3 2024 Earnings Conference Call October 30, 2024 8:00 AM ET Company Participants Ingrid Goldberg - IR Bill Doyle - Chairman Ashley Cordova - CFO Asaf Danziger - CEO Frank Leonard - EVP and President of NovoCure Oncology Nicolas Leupin - Chief Medical Officer Conference Call Participants Jason Bednar - Piper Sandler Jonathan Chang - Leerink Partners Emily Bodnar ...
More Novocure Ltd. News

Company Profile

NovoCure Ltd. develops treatment for tumors. Its platform is called the Tumor Treating Field which used electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.

Head office Jersey
CEO Asaf Danziger
Employees 1,453
Founded 2000
Website www.novocure.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today